Physician profile
Siva Arunasalam
NPI 1609806041
$37,529.02
in general payments reported to CMS, 2019-2025
59 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,243 · 2021: $3,874 · 2022: $11K · 2023: $1,867 · 2024: $3,454 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,255 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,254.75 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,641.58 | 2021-2025 | Onyx Frontier, Symplicity G3, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $6,292.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,182.98 | 2019-2025 | |
| Shockwave Medical, INC | $3,821.51 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cathworks, INC. | $2,140.00 | 2021 | |
| Medtronic Vascular, INC. | $1,778.67 | 2020 | |
| Merck Sharp & Dohme LLC | $1,280.77 | 2021-2025 | Verquvo, Winrevair, Belsomra |
| Biotronik INC. | $981.61 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Janssen Pharmaceuticals, INC | $708.70 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $673.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.26 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $486.70 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $482.46 | 2019-2025 | |
| Novo Nordisk INC | $389.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Inari Medical, INC. | $323.14 | 2021-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $310.65 | 2023-2024 | |
| Heartflow, INC. | $305.31 | 2021-2024 | |
| Boston Scientific Corporation | $270.95 | 2020-2024 | |
| Cardiovascular Systems INC. | $248.25 | 2019-2023 | Diamondback Coronary |
| Baxter Healthcare | $209.55 | 2022-2025 | Hillrom - Volara System, Hillrom - Monarch Airway Clearance System |
| E.R. Squibb & Sons, L.L.C. | $207.78 | 2022-2025 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $146.17 | 2019-2022 | |
| Abbott Laboratories | $135.45 | 2021-2024 | Diamondback Coronary |
| Welch Allyn | $134.69 | 2021 | |
| Elutia, INC. | $133.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $109.87 | 2019-2024 | |
| United Therapeutics Corporation | $109.17 | 2019-2025 | Tyvaso |
| Abiomed | $107.11 | 2020-2025 | |
| Vital Connect, INC | $102.45 | 2022 | |
| Abbvie INC. | $93.23 | 2020-2024 | Ubrelvy |
| Allergan, INC. | $85.14 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $84.14 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.06 | 2020-2023 | Lifevest |
| Edwards Lifesciences Corporation | $79.75 | 2021-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $66.20 | 2021 | |
| Amgen INC. | $65.27 | 2019-2022 | |
| Astellas Pharma US INC | $63.10 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $58.88 | 2023 | Inpefa |
| Kestra Medical Technology Services, INC. | $57.28 | 2022-2024 | Assure Wcd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.81 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $50.93 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $40.18 | 2020-2023 | C3 Delivery System |
| Lilly USA, LLC | $39.87 | 2020-2021 | |
| Mylan Specialty L.P. | $28.98 | 2019-2023 | Yupelri |
| Philips North America LLC | $28.84 | 2019-2024 | (8874) Incourage |
| Eisai INC. | $25.11 | 2020-2021 | |
| Bridgebio Pharma, INC. | $20.57 | 2025 | Attruby |
| Cordis US Corp. | $20.25 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.78 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $18.58 | 2019 | |
| Vifor Pharma, INC. | $18.03 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.61 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $17.30 | 2022 | |
| Vivus LLC | $16.19 | 2024 | Pancreaze |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.18 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.99 | 2020 | |
| Glaxosmithkline, LLC. | $15.20 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $13.87 | 2024 | Arcalyst |
| Smith+Nephew, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siva Arunasalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.